FDA 483 - ONESOURCE SPECIALTY PHARMA LIMITED - July 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Stelis Biopharma Limited, a drug manufacturer in Bengaluru, India, was cited for five observations during an FDA inspection. Key issues include inadequate equipment design and control, insufficient computer system controls, deficiencies in container closure system protection, failures in quality control unit procedures and documentation practices, and incomplete laboratory records regarding sample receipt dates. The observations indicate significant concerns with manufacturing and quality control processes.
ID · e292d2c2-10b3-442e-b3b9-e20011133854